Abbott, a health care company, has unveiled a bioresorbable vascular scaffold (BVS) in Europe, parts of Asia Pacific and Latin America to treat patients with coronary artery disease (CAD).
The Absorb drug eluting vascular scaffold, which is made of a naturally polylactide material, gets dissolved within the vessel and increases the blood flow to the heart.
The BVS also delivers an anti-proliferative drug, everolimus, that inhibits in-stent neointimal growth in the coronary vessels following stent implantation.
The international launch of Absorb is based on a clinical trial program that includes five studies, conducted in more than 20 countries.
The study data demonstrated that Absorb can provide traditional measures similar to a drug eluting stent including major adverse cardiovascular events and target lesion revascularization.
Erasmus University Hospital interventional cardiology professor Patrick W. Serruys said, "With the launch of Absorb, a scaffold that disappears after doing its job is no longer a dream, but a reality."
Absorb BVS, which is currently in development, is neither approved nor authorized for sale in the US, according to the company.